$Biodexa Pharmaceuticals (BDRX.US)$ hmm. I wonder about this one

$Biodexa Pharmaceuticals (BDRX.US)$ do well on open?

$Biodexa Pharmaceuticals (BDRX.US)$
Clinical Breakthrough: Biodexa's FAP Drug Shows 89% Success Rate, Earns Fast Track Status

$Biodexa Pharmaceuticals (BDRX.US)$ Reprint FDA news from 2 days ago is one way to get a price move! Hehehe

$Biodexa Pharmaceuticals (BDRX.US)$ Biodexa Pharmaceuticals (NASDAQ:BDRX) has received FDA Fast Track status for eRapa, its drug treating familial adenomatous polyposis (FAP), following positive Phase 2 results and Orphan Drug designation. The Phase 2 trial showed promising results with a 17% median decrease in overall polyp burden and 75% non-progression rate. Notably, cohort 2 demonstrated an 89% non-progression rate and 29% median reduction in polyp burden at 12 months.
FAP is an inherited co...

$Biodexa Pharmaceuticals (BDRX.US)$ back to previous price while getting fast track is crazy. Keep a watch out

$Biodexa Pharmaceuticals (BDRX.US)$ scalp it but be careful, offering sometime

$Biodexa Pharmaceuticals (BDRX.US)$ lets start

$Biodexa Pharmaceuticals (BDRX.US)$ waiting 🤔🫣